Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Abstract excerpt

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the most important targets for drug development in oncology. Monoclonal antibodies targeting the external domain of EGFR have been shown to have clinical benefit in colorectal and head and neck cancer when combined with chemotherapy and/or radiation. Small molecules that inhibit the tyrosine kinase (TK) domain of EGFR have...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Erlotinib Hydrochloride
• Share to Gefitinib